Aristolochia clematitis

Aristolochic acid causes kidney damage through direct toxicity to renal tubular cells, forming DNA adducts that lead to mutations and progressive cell death. The compound is metabolized in the kidneys, where it accumulates and triggers interstitial fibrosis. This mechanism results in aristolochic acid nephropathy, characterized by rapidly progressive kidney failure. Evidence Level B studies confirm that aristolochic acid I and II are the primary nephrotoxic compounds, with cumulative and often irreversible effects even after exposure ceases.

Aristolochia clematitis is absolutely unsafe during pregnancy and breastfeeding. Historically, it was used to stimulate childbirth, indicating it can cause uterine contractions and potential miscarriage. The aristolochic acids cross the placental barrier and are excreted in breast milk, posing severe risks to fetal and infant kidney development. Evidence Level B confirms teratogenic and nephrotoxic effects. Pregnant or breastfeeding individuals should avoid all contact with this herb. The European Union has banned its use in any medicinal context due to these documented dangers.

There is no recommended safe dosage of Aristolochia clematitis. The herb is contraindicated for all internal use due to aristolochic acids, which cause irreversible kidney damage and increase cancer risk. Regulatory agencies including the EU have banned all Aristolochia species from medicinal products. Even small amounts can cause cumulative toxicity. Historical texts may reference dosages for childbirth or wound healing, but these uses are considered dangerous and obsolete given modern understanding of the herb's severe toxicity profile.

Aristolochia clematitis is contraindicated for use with any medications due to its severe nephrotoxicity. The herb should never be consumed internally. While specific drug interaction studies are limited (Evidence Level D), the kidney damage caused by aristolochic acids could alter the metabolism and elimination of numerous drugs processed through renal pathways. Combining this herb with other nephrotoxic substances, including certain NSAIDs and antibiotics, could compound kidney damage. No internal use is considered safe under any circumstances.

Aristolochia species are banned in the European Union and many other jurisdictions due to documented cases of severe kidney damage and urinary tract cancers. The ban followed the discovery of aristolochic acid nephropathy in the 1990s, when patients taking Chinese herbal weight loss products containing Aristolochia developed end-stage renal disease. Evidence Level B studies established that aristolochic acids are both nephrotoxic and carcinogenic, causing urothelial carcinoma. The International Agency for Research on Cancer classifies aristolochic acid as a Group 1 carcinogen.